BioAtla (NASDAQ:BCAB) Trading Up 11.1% – Still a Buy?

BioAtla, Inc. (NASDAQ:BCAB)’s stock price was up 11.1% during trading on Wednesday . The company traded as high as $0.2158 and last traded at $0.2099. Approximately 1,771,462 shares traded hands during trading, a decline of 44% from the average daily volume of 3,153,160 shares. The stock had previously closed at $0.1890.

Analyst Ratings Changes

Several analysts have recently issued reports on the company. Rodman & Renshaw started coverage on BioAtla in a research report on Tuesday, January 13th. They issued a “buy” rating and a $4.00 price objective on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioAtla in a research report on Friday, January 9th. One analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $4.00.

BioAtla Price Performance

The firm has a market cap of $13.32 million, a PE ratio of -0.18 and a beta of 1.10. The stock has a 50-day moving average price of $0.56 and a 200 day moving average price of $0.60.

BioAtla (NASDAQ:BCAB) last released its earnings results on Thursday, November 13th. The company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.04. As a group, equities research analysts anticipate that BioAtla, Inc. will post -1.46 earnings per share for the current year.

Institutional Investors Weigh In On BioAtla

A number of institutional investors have recently bought and sold shares of BCAB. Acorn Capital Advisors LLC raised its stake in BioAtla by 19.9% during the second quarter. Acorn Capital Advisors LLC now owns 4,835,111 shares of the company’s stock worth $1,915,000 after purchasing an additional 803,065 shares during the period. Vanguard Group Inc. increased its holdings in shares of BioAtla by 9.1% during the 3rd quarter. Vanguard Group Inc. now owns 1,945,795 shares of the company’s stock worth $1,339,000 after buying an additional 162,647 shares during the last quarter. Acadian Asset Management LLC increased its holdings in shares of BioAtla by 968.9% during the 1st quarter. Acadian Asset Management LLC now owns 1,690,110 shares of the company’s stock worth $585,000 after buying an additional 1,531,994 shares during the last quarter. Millennium Management LLC purchased a new position in shares of BioAtla in the 3rd quarter worth $235,000. Finally, Susquehanna International Group LLP boosted its holdings in BioAtla by 237.6% in the third quarter. Susquehanna International Group LLP now owns 252,583 shares of the company’s stock valued at $174,000 after acquiring an additional 177,760 shares during the last quarter. 77.23% of the stock is currently owned by hedge funds and other institutional investors.

BioAtla Company Profile

BioAtla, Inc (NASDAQ: BCAB) is a clinical‐stage biotechnology company focused on the development of conditionally active biologics (CABs) for oncology and other serious diseases. Utilizing its proprietary CAB technology platform, BioAtla engineers monoclonal antibodies, bispecifics and antibody-drug conjugates that remain inactive in healthy tissues but become activated in the tumor microenvironment. This targeted approach aims to improve therapeutic index by enhancing anti‐tumor potency while minimizing off-target effects and systemic toxicity.

Founded in 2012 and headquartered in San Diego, California, BioAtla has advanced multiple product candidates into clinical trials.